Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?

Authors: Angelika Tölle, Monika Jung, Michael Lein, Manfred Johannsen, Kurt Miller, Holger Moch, Klaus Jung, Glen Kristiansen

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

Renal cell carcinoma (RCC) is the most common renal neoplasm. Cancer tissue is often characterized by altered energy regulation. Fatty acid-binding proteins (FABP) are involved in the intracellular transport of fatty acids (FA). We examined the level of brain-type (B) and liver-type (L) FABP mRNA and the protein expression profiles of both FABPs in renal cell carcinoma.

Methods

Paired tissue samples of cancerous and noncancerous kidney parts were investigated. Quantitative RT-PCR, immunohistochemistry and western blotting were used to determine B- and L-FABP in tumor and normal tissues. The tissue microarray (TMA) contained 272 clinico-pathologically characterized renal cell carcinomas of the clear cell, papillary and chromophobe subtype. SPSS 17.0 was used to apply crosstables (χ2-test), correlations and survival analyses.

Results

B-FABP mRNA was significantly up-regulated in renal cell carcinoma. In normal tissue B-FABP mRNA was very low or often not detectable. RCC with a high tumor grading (G3 + G4) showed significantly lower B-FABP mRNA compared with those with a low grading (G1 + G2). Western blotting analysis detected B-FABP in 78% of the cases with a very strong band but in the corresponding normal tissue it was weak or not detectable. L-FABP showed an inverse relationship for mRNA quantification and western blotting. A strong B-FABP staining was present in 52% of the tumor tissues contained in the TMA. In normal renal tissue, L-FABP showed a moderate to strong immunoreactivity in proximal tubuli. L-FABP was expressed at lower rates compared with the normal tissues in 30.5% of all tumors. There was no correlation between patient survival times and the staining intensity of both FABPs.

Conclusion

While B-FABP is over expressed in renal cell carcinoma in comparison to normal renal tissues L-FABP appears to be reduced in tumor tissue. Although the expression behavior was not related to the survival outcome of the RCC patients, it can be assumed that these changes indicate fundamental alterations in the fatty metabolism in the RCC carcinogenesis. Further studies should identify the role of both FABPs in carcinogenesis, progression and with regard to a potential target in RCC.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al: Cancer statistics, 2008. CA Cancer J Clin. 2008, 58: 71-96. 10.3322/CA.2007.0010.CrossRefPubMed
2.
Schrader AJ, Varga Z, Hegele A, Pfoertner S, Olbert P, Hofmann R: Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol. 2006, 132: 137-149. 10.1007/s00432-005-0058-4.CrossRefPubMed
3.
Gesellschaft der epidemiologischen Krebsregister in Deutschland. 6. 2008, Auflage, Robert Koch Institute, Berlin
4.
Escudier B: Advanced renal cell carcinoma: current and emerging management strategies. Drugs. 2007, 67: 1257-1264. 10.2165/00003495-200767090-00002.CrossRefPubMed
5.
Pittoggi C, Martis G, Mastrangeli G, Mastrangeli B, Spadafora C: In vitro evidence for a new therapeutic approach in renal cell carcinoma. Int Braz J Urol. 2008, 34: 492-502. 10.1590/S1677-55382008000400012.CrossRefPubMed
6.
Glatz JF, van Nieuwenhoven FA, Luiken JJ, Schaap FG, Vusse van der GJ: Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism. Prostaglandins Leukot Essent Fatty Acids. 1997, 57: 373-378. 10.1016/S0952-3278(97)90413-0.CrossRefPubMed
7.
Furuhashi M, Hotamisligil GS: Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov. 2008, 7: 489-503. 10.1038/nrd2589.CrossRefPubMedPubMedCentral
8.
Hammamieh R, Chakraborty N, Das R, Jett M: Molecular impacts of antisense complementary to the liver fatty acid binding protein (FABP) mRNA in DU 145 prostate cancer cells in vitro. J Exp Ther Oncol. 2004, 4: 195-202.PubMed
9.
Hammamieh R, Chakraborty N, Barmada M, Das R, Jett M: Expression patterns of fatty acid binding proteins in breast cancer cells. J Exp Ther Oncol. 2005, 5: 133-143.PubMed
10.
Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE: Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol Cell Proteomics. 2005, 4: 570-581. 10.1074/mcp.M500017-MCP200.CrossRefPubMed
11.
Mita R, Coles JE, Glubrecht DD, Sung R, Sun X, Godbout R: B-FABP-expressing radial glial cells: the malignant glioma cell of origin?. Neoplasia. 2007, 9: 734-744. 10.1593/neo.07439.CrossRefPubMedPubMedCentral
12.
Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, et al: Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005, 11: 5730-5739. 10.1158/1078-0432.CCR-04-2225.CrossRefPubMed
13.
Seliger B, Lichtenfels R, Atkins D, Bukur J, Halder T, Kersten M, et al: Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics. 2005, 5: 2631-2640. 10.1002/pmic.200401264.CrossRefPubMed
14.
Maatman RG, van Kuppevelt TH, Veerkamp JH: Two types of fatty acid-binding protein in human kidney. Isolation, characterization and localization. Biochem J. 1991, 273 (Pt 3): 759-766.CrossRefPubMedPubMedCentral
15.
Kimura H, Fujii H, Suzuki S, Ono T, Arakawa M, Gejyo F: Lipid-binding proteins in rat and human kidney. Kidney Int Suppl. 1999, 71: S159-S162. 10.1046/j.1523-1755.1999.07141.x.CrossRefPubMed
16.
Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006, 49: 798-805. 10.1016/j.eururo.2005.11.035.CrossRefPubMed
17.
Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, et al: In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol. 2007, 8: 47-10.1186/1471-2199-8-47.CrossRefPubMedPubMedCentral
18.
Fritzsche FR, Jung M, Tolle A, Wild P, Hartmann A, Wassermann K, et al: ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer. Eur Urol. 2008, 54: 1097-1106. 10.1016/j.eururo.2007.11.034.CrossRefPubMed
19.
Patard JJ, Pantuck AJ, Crepel M, Lam JS, Bellec L, Albouy B, et al: Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. Eur Urol. 2007, 52: 148-154. 10.1016/j.eururo.2007.01.039.CrossRefPubMed
20.
Nikiforova NV, Kirpatovsky VI, Darenkov AF, Chumakov AM, Sevrukov EA, Darenkov SP: Liposoluble vitamins E and A in human renal cortex and renal cell carcinomas. Nephron. 1995, 69: 449-453. 10.1159/000188518.CrossRefPubMed
21.
Horiguchi A, Asano T, Asano T, Ito K, Sumitomo M, Hayakawa M: Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma. J Urol. 2008, 180: 1137-1140. 10.1016/j.juro.2008.04.135.CrossRefPubMed
22.
Glatz JF, Storch J: Unravelling the significance of cellular fatty acid-binding proteins. Curr Opin Lipidol. 2001, 12: 267-274. 10.1097/00041433-200106000-00005.CrossRefPubMed
23.
Glatz JFC, Voort van der D, Hermens WT: Fatty Acid-binding Protein as the Earliest Available Plasma Marker of Acute Myocardial Injury. Clinical Ligand Assay. 2002, 25: 167-177.
24.
Pelsers MM, Hermens WT, Glatz JF: Fatty acid-binding proteins as plasma markers of tissue injury. Clin Chim Acta. 2005, 352: 15-35. 10.1016/j.cccn.2004.09.001.CrossRefPubMed
25.
Guthmann F, Schachtrup C, Tolle A, Wissel H, Binas B, Kondo H, et al: Phenotype of palmitic acid transport and of signalling in alveolar type II cells from E/H-FABP double-knockout mice: contribution of caveolin-1 and PPARgamma. Biochim Biophys Acta. 2004, 1636: 196-204.CrossRefPubMed
26.
Lachmann RA, Werchan S, Schachtrup C, Haitsma JJ, Spener F, Lachmann B: Liver-type fatty acid binding protein in serum and broncho-alveolar lavage in a model of acute respiratory failure because of surfactant depletion – a possible marker for lung damage?. Clin Physiol Funct Imaging. 2006, 26: 371-375. 10.1111/j.1475-097X.2006.00703.x.CrossRefPubMed
27.
Masouye I, Saurat JH, Siegenthaler G: Epidermal fatty-acid-binding protein in psoriasis, basal and squamous cell carcinomas: an immunohistological study. Dermatology. 1996, 192: 208-213.CrossRefPubMed
28.
Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K: Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol. 2006, 26: 82-86. 10.1159/000091956.CrossRefPubMed
29.
Hofstra JM, Deegens JK, Steenbergen EJ, Wetzels JF: Urinary excretion of fatty acid-binding proteins in idiopathic membranous nephropathy. Nephrol Dial Transplant. 2008, 23: 3160-3165. 10.1093/ndt/gfn190.CrossRefPubMed
30.
Morgan EA, Forootan SS, Adamson J, Foster CS, Fujii H, Igarashi M, et al: Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: Potential prognostic marker and target for tumourigenicity-suppression. Int J Oncol. 2008, 32: 767-775.PubMed
31.
Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, et al: Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. Cancer Res. 1997, 57: 4111-4117.PubMed
32.
Teratani T, Domoto T, Kuriki K, Kageyama T, Takayama T, Ishikawa A, et al: Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology. 2007, 69: 236-240. 10.1016/j.urology.2006.09.060.CrossRefPubMed
33.
Wolfrum C, Borrmann CM, Borchers T, Spener F: Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha – and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus. Proc Natl Acad Sci USA. 2001, 98: 2323-2328. 10.1073/pnas.051619898.CrossRefPubMedPubMedCentral
34.
Kristiansen G, Jacob J, Buckendahl AC, Grutzmann R, Alldinger I, Sipos B, et al: Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times. Clin Cancer Res. 2006, 12: 6444-6451. 10.1158/1078-0432.CCR-06-0834.CrossRefPubMed
Metadata
Title
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
Authors
Angelika Tölle
Monika Jung
Michael Lein
Manfred Johannsen
Kurt Miller
Holger Moch
Klaus Jung
Glen Kristiansen
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-248

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue

Research article

The striking geographical pattern of gastric cancer mortality in Spain: environmental hypotheses revisited

Research article

The prognostic value of four interleukin-1 gene polymorphisms in caucasian women with breast cancer – a multicenter study

Research article

Clinical significance of Neutrophil gelatinase-associated lipocalin(NGAL) expression in primary rectal cancer

Research article

Histological evaluation of AMPK signalling in primary breast cancer

Research article

Groucho binds two conserved regions of LEF-1 for HDAC-dependent repression

Research article

Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits